GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Long-Term Debt

IONS (Ionis Pharmaceuticals) Long-Term Debt : $1,250.7 Mil (As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is Ionis Pharmaceuticals Long-Term Debt?

Ionis Pharmaceuticals's Long-Term Debt for the quarter that ended in Mar. 2025 was $1,250.7 Mil.

Ionis Pharmaceuticals's quarterly Long-Term Debt increased from Sep. 2024 ($1,233.8 Mil) to Dec. 2024 ($1,245.5 Mil) and increased from Dec. 2024 ($1,245.5 Mil) to Mar. 2025 ($1,250.7 Mil).

Ionis Pharmaceuticals's annual Long-Term Debt increased from Dec. 2022 ($1,182.7 Mil) to Dec. 2023 ($1,229.5 Mil) and increased from Dec. 2023 ($1,229.5 Mil) to Dec. 2024 ($1,245.5 Mil).

Ionis Pharmaceuticals Long-Term Debt Historical Data

The historical data trend for Ionis Pharmaceuticals's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ionis Pharmaceuticals Long-Term Debt Chart

Ionis Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 600.12 1,228.09 1,182.72 1,229.50 1,245.49

Ionis Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,230.93 1,232.38 1,233.82 1,245.49 1,250.72

Ionis Pharmaceuticals  (NAS:IONS) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Ionis Pharmaceuticals Long-Term Debt Related Terms

Thank you for viewing the detailed overview of Ionis Pharmaceuticals's Long-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Ionis Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ionis Pharmaceuticals Inc (NAS:IONS) » Definitions » Long-Term Debt
Comparable Companies
LEGN HALO JAZZ MDGL TGTX RVMD NUVL CAI AXSM ROIV VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:UCB XBRU:ARGX ONC XKRX:068270 BNTX
Traded in Other Exchanges
0JDI:UK ISI:Germany ISI:Germany
Address
2855 Gazelle Court, Carlsbad, CA, USA, 92010
Website
https://www.ionis.com
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
Executives
Michael R Hayden director C/O ASPREVA PHARMACEUTICALS CORPORATION, 1203-4464 MARKHAM STREET, VICTORIA A1 V8Z 7X8
Brian Birchler officer: EVP, Corp and Development Ops C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Joseph Baroldi officer: Chief Business Officer C/O IONIS PHARMACEUTICALS, INC., C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Brett P Monia director, officer: Senior Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Patrick R. O'neil officer: SVP, Legal and General Counsel C/O IONIS PHARMACEUTICALS, INC., 2855 GAZELLE COURT, CARLSBAD CA 92010
Eugene Schneider officer: EVP, Chf Clinical Develop Offc C/O IONIS PHARMACEUTICALS, 2855 GAZELLE CT, CARLSBAD CA 92010
Eric Swayze officer: SVP, Research 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Richard S Geary officer: Senior Vice President 2855 GAZELLE COURT, 2855 GAZELLE COURT, CARLSBAD CA 92010
Elizabeth L Hougen officer: SVP, Finance and CFO 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
C Frank Bennett officer: Vice President 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010
Joseph Loscalzo director
Allene M. Diaz director C/O ALLENA PHARMACEUTIALS, INC., ONEW NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA 02462
Joseph Iii Klein director C/O GENAISSANCE PHARMACEUTICALS INC, FIVE SCIENCE PARK, NEW HAVEN CT 06511
Spencer R Berthelsen director 2855 GAZELLE COURT, CARLSBAD CA 92010
Onaiza Cadoret-manier officer: Chief Corp Dev and Cml Officer 2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010